Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
MetadataShow full item record
Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and increased metabolic and cardiovascular risks. The GnRH antagonist relugolix is able to reduce serum testosterone levels in men with prostate cancer without inducing testosterone flare. In the HERO Phase III trial, relugolix was superior to leuprolide acetate at rapidly reducing testosterone and continuously suppressing testosterone, with faster post-treatment recovery of testosterone levels. Relugolix was associated with a 54% lower incidence of major adverse cardiovascular events than leuprolide acetate. As the first oral GnRH antagonist approved for the treatment of advanced prostate cancer, relugolix offers a new treatment option.
Randomized Controlled Trials as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Clinical Academic Radiotherapy (Dearnaley)
Future oncology (London, England), 2021, 17 (33), pp. 4431 - 4446